Navigation Links
3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
Date:1/28/2008

SHENYANG, China, Jan. 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Kevin Teo to the position of Chief Financial Officer effective January 28, 2008. Mr. Teo will replace Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008.

Dr. Jing Lou, CEO of 3SBio, commented, "I am pleased to welcome Kevin Teo to 3SBio's senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin's ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors."

Mr. Teo, 42, brings to 3SBio over 20 years of relevant experience, having held a number of senior finance and accounting positions in the energy and technology industries throughout Asia. Most recently, he served as Group Business Controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing and Beijing. His responsibilities included, but were not limited to, the implementation of company-wide internal control procedures and policies, oversight of the company's monthly financial statements and position, liaison with corporate departments, interaction with external parties and advisors, and coordination of annual audits at subsidiary and group levels.

Prior to his employment with East Asia Power (Xiamen), Mr. Teo held senior roles at Huawei Technologies Co. Ltd. (Shenzhen), Siemens Malaysia Sdn. Bhd., Siemens Cerberus Sdn. Bhd., Wetlands International - Asia Pacific, Chua Song Seng Sdn. Bhd., and Anuarul Azizan Chew & Co. Mr. Teo received a London Chamber of Commerce and Industry Third Level Group Diploma in Cost Accounting and a Pitman Certificate in Advanced Accounting in 1989. He is also a member of the Association of Chartered Certified Accountants since 1995 and received a certificate in International Financial Reporting Standards in 2006. He attended the Master of Laws in International Business Law accredited by School of Law, Staffordshire University in the U.K. He has been a member of the Malaysian Institute of Accountants since 1996.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

For more information, please contact:

Investor Contact:

Clara Mak, CFO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations(HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Investor Relations(US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
2. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
3. 3SBio Inc. to Hold Annual General Meeting
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
7. Hoya Announces Third Quarter and Nine Month Results for 2007
8. Medefield Announces New Appointments to North American Business Unit
9. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
10. US Oncology Announces Realignment of Executive Team
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal ... using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining ... a compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone Partners ... commitment to the advancement of the clinical trials segment. Hosted in Miami, this ... trial planning and management. , As executive talent specialists in the industries ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):